Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures H1 2026: Net sales strongly up, earnings significantly above the prior year – positive earnings outlook

Lübeck, July 13, 2026 – Based on preliminary calculations, Dräger’s net sales rose by 7.7 percent (net of currency effects; nominal: 6.2 percent) in the first half 2026. At around EUR 1,603 million, it was around EUR 93 million above the prior-year figure (6 months 2025: EUR 1,510.2 million). Both divisions were able to grow: the medical division recorded an increase of 7.6 percent (net of currency effects; nominal: 5.5 percent) to around EUR 898 million (6 months 2025: EUR 851.1 million), while the safety division reported an increase of 7.8 percent (net of currency effects; nominal: 7.0 percent) to around EUR 706 million (6 months 2025: EUR 659.2 million) following a decline in the prior-year period.

Earnings before interest and taxes (EBIT) more than tripled, rising to around EUR 64 million (6 months 2025: EUR 20.4 million). The EBIT margin also increased very significantly to around 4.0 percent (6 months 2025: 1.3 percent). The main reasons for this were strong net sales growth and the improvement in the gross margin to around 46.5 percent (6 months 2025: 44.8 percent). Functional expenses rose by 3.6 percent to around EUR 681 million (6 months 2025: EUR 656.9 million). The increase in expenses thus remained significantly below net sales growth. In addition, EBIT included a one-off effect of EUR 7.8 million from refunded customs payments.

Order intake increased by 1.8 percent (net of currency effects; nominal: 0.5 percent) to around EUR 1,747 million (6 months 2025: EUR 1,738.0 million). In the safety division, it rose significantly by 9.5 percent (net of currency effects; nominal: 8.8 percent) to around EUR 791 million (6 months 2025: EUR 727.2 million). In the medical division, order intake declined by 3.7 percent (net of currency effects; nominal: -5.4 percent) to around EUR 956 million (6 months 2025: EUR 1,010.8 million). The main reason for this was the high prior-year level: in the second quarter of 2025, Dräger had received a major order for hospital infrastructure systems from Mexico. Adjusted for this order, order intake in the medical division would have remained roughly stable in the first half 2026.

Business performance in the second quarter of 2026
In the second quarter, order intake of around EUR 883 million was 0.3 percent (net of currency effects; nominal: 0.6 percent) above the prior-year figure (Q2 2025: EUR 877.2 million). The safety division recorded strong growth of 19.0 percent (net of currency effects; nominal: 19.4 percent) to around EUR 406 million (Q2 2025: EUR 340.1 million), thanks to overall very good demand. In the medical division, order intake fell significantly, primarily due to the Mexico effect: at around EUR 477 million, the volume was 11.5 percent lower (net of currency effects; nominal: -11.3 percent) than the prior-year level (Q2 2025: EUR 537.1 million).

Net sales increased by 8.5 percent (net of currency effects; nominal: 8.6 percent) to around EUR 847 million (Q2 2025: EUR 780.0 million). Both divisions grew: the medical division recorded significant growth of 9.7 percent (net of currency effects; nominal: 9.6 percent) to around EUR 480 million (Q2 2025: EUR 438.0 million), while the safety division reported an increase of 6.9 percent (net of currency effects; nominal: 7.4 percent) to around EUR 367 million (Q2 2025: EUR 342.0 million). The Group’s gross margin climbed to around 46.6 percent (Q2 2025: 43.8 percent). EBIT more than doubled, rising to around EUR 46 million (Q2 2025: EUR 20.0 million). The EBIT margin also improved significantly to around 5.4 percent (Q2 2025: 2.6 percent).

Forecast for 2026
For the current fiscal year, Dräger expects an increase in net sales of 2.0 to 6.0 percent (net of currency effects). Due to the strong operating business performance and the customs refunds received, the lower end of the forecast range for the EBIT margin is being raised. Accordingly, Dräger now expects an EBIT margin of 5.5 to 7.5 percent (previously 5.0 to 7.5 percent).

The half-yearly financial report 2026 will be published on July 30, 2026.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Ulrike Abratis
Tel. +49 451 882-3202
ulrike.abratis@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

2365118  13-Jul-2026 CET/CEST